Article
Oncology
Liam S. P. Lawrence, Rachel W. Chan, Hanbo Chen, Brian Keller, James Stewart, Mark Ruschin, Brige Chugh, Mikki Campbell, Aimee Theriault, Greg J. Stanisz, Scott MacKenzie, Sten Myrehaug, Jay Detsky, Pejman J. Maralani, Chia-Lin Tseng, Greg J. Czarnota, Arjun Sahgal, Angus Z. Lau
Summary: This study evaluated the accuracy and precision of ADC measurements from DWI on a 1.5 T MR-Linac in CNS tumor patients compared to a diagnostic scanner. Results showed small biases in ADC measurements between MR-Linac and Ingenia scans, with substantial differences in CSF. Repeatability of ADC measurements over white/grey matters was similar to previous reports, and changes in ADC within the GTV were detectable.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Jonas Habrich, Simon Boeke, Marcel Nachbar, Konstantin Nikolaou, Fritz Schick, Cihan Gani, Daniel Zips, Daniela Thorwarth
Summary: This study assessed the repeatability of ADC derived from EPI DW-MRI in HNC using a 1.5T MR-Linac. The results demonstrated good repeatability of ADC values, suggesting its potential use in future biologically adapted MR-guided radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Oncology
Katharina Witzmann, Felix Raschke, Esther G. C. Troost
Summary: Radiotherapy is a crucial treatment against cancer, but it can lead to damage in surrounding normal tissues, affecting quality of life. Studies have shown that radiation induces morphologic, microstructural, vascular, and metabolic changes in brain tissues.
Review
Oncology
Raphaele Renard-Penna, Jules Zhang-Yin, Sarah Montagne, Laurene Aupin, Eric Bruguiere, Mouna Labidi, Igor Latorzeff, Christophe Hennequin
Summary: Magnetic resonance imaging (MRI) plays a crucial role in the management of prostate cancer, allowing for detection of recurrence, guidance of radiation therapy, and localization of recurrent tumors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Urology & Nephrology
Shalini Moningi, Atish D. Choudhury, Neil E. Martin, Paul L. Nguyen, Anthony V. D'Amico, Daniel N. Cagney, Jonathan E. Leeman
Summary: Prostate SMART was found to be well tolerated and all patients had local control of disease within the prostate at the time of last follow-up. Prostate SMART may represent a low-risk and well-tolerated approach for delivering prostate-directed radiotherapy for patients with limited metastatic disease.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Matthew Gibbons, Olga Starobinets, Jeffry P. Simko, John Kurhanewicz, Peter R. Carroll, Susan M. Noworolski
Summary: This study aimed to characterize the MR signatures of various benign prostate tissues and differentiate them from cancer using mpMRI. The study demonstrated the capability of mpMRI to discriminate between benign and cancerous tissues effectively.
MAGNETIC RESONANCE IMAGING
(2022)
Article
Engineering, Biomedical
Jeremy S. Bredfeldt, Xin Miao, Evangelia Kaza, Manuel Schneider, Martin Requardt, Thorsten Feiweier, Ayal Aizer, Shyam Tanguturi, Daphne Haas-Kogan, Rifaquat Rahman, Daniel N. Cagney, Atchar Sudhyadhom
Summary: The objective of this study is to mitigate patient-specific distortion in MRI-based radiation therapy planning. A technique for distortion detection and mitigation on a patient specific basis was investigated. The results showed that the method for B0 mapping was valid and could assess distortion clinically.
PHYSICS IN MEDICINE AND BIOLOGY
(2022)
Article
Oncology
Or Gelbart Pridan, Merav Akiva Ben David, Svetlana Zalmanov, Yoav Lipski, Vladislav Grinberg, Daphne Levin, Sara Apter, Michal Guindi, Dan Epstein, Roman Radus, Orit Arsenault, Keren Hod, Qusai Tamami, Raphael Pfeffer
Summary: We present our experience with MR-guided stereotactic body radiotherapy (SBRT) for 200 consecutive patients with prostate cancer. Treatment planning included fusion of the 0.35-Tesla planning MRI with multiparametric MRI and PET-PSMA for Group Grade (GG) 2 or higher. No fiducials or rectal spacers were used. The prostate was monitored during treatment that was automatically interrupted if the target moved out of the PTV range.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Laila A. Gharzai, Ralph Jiang, David Wallington, Gavin Jones, Samuel Birer, Neil Jairath, Elizabeth M. Jaworski, Matthew R. McFarlane, Brandon A. Mahal, Paul L. Nguyen, Howard Sandler, Todd M. Morgan, Zachery R. Reichert, Joshi J. Alumkal, Rohit Mehra, Amar U. Kishan, Karim Fizazi, Susan Halabi, Edward M. Schaeffer, Felix Y. Feng, David Elliott, Robert T. Dess, William C. Jackson, Matthew J. Schipper, Daniel E. Spratt
Summary: This study comprehensively assessed the performance of commonly reported intermediate clinical endpoints in all randomized trials in localized prostate cancer, and found that metastasis-free survival is the only identified surrogate endpoint for overall survival to date.
Article
Radiology, Nuclear Medicine & Medical Imaging
Esteban Lucas Solari, Andrei Gafita, Sylvia Schachoff, Borjana Bogdanovi, Alberto Villagran Asiares, Thomas Amiel, Wang Hui, Isabel Rauscher, Dimitris Visvikis, Tobias Maurer, Kristina Schwamborn, Mona Mustafa, Wolfgang Weber, Nassir Navab, Matthias Eiber, Mathieu Hatt, Stephan G. Nekolla
Summary: The study evaluated the performance of combined PET and mpMRI radiomics for predicting postsurgical Gleason scores in primary prostate cancer patients. The results showed that the PET + ADC double-modality model performed the best, significantly outperforming other models, and had better predictive ability for psGS compared to biopsy GS.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Kobika Sritharan, Alison Tree
Summary: Advancements in radiotherapy technology have improved treatment precision. The new generation of MRI-guided radiotherapy machines has the potential to revolutionize cancer treatment, especially for prostate cancer.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Biology
Yvonne Wimper, Jurgen J. Futterer, Joyce G. R. Bomers
Summary: MRI-guided therapy plays an important role in the treatment of prostate cancer, providing accurate lesion targeting and real-time treatment monitoring. Cryoablation, focal laser ablation, high intensity focused ultrasound, and transurethral ultrasound ablation are widely used in personalized treatment. However, these new technologies still face challenges and require further development.
Article
Radiology, Nuclear Medicine & Medical Imaging
S. Tahri, A. Barateau, C. Cadin, H. Chourak, S. Ribault, F. Nozahic, O. Acosta, J. A. Dowling, P. B. Greer, A. Largent, C. Lafond, R. De Crevoisier, J. C. Nunes
Summary: The study on generating sCT images from MRI data using the Pix2Pix architecture shows that this method has the lowest imaging errors and similar dose uncertainties compared to other deep learning methods, making it a more superior option for prostate radiotherapy planning.
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
(2022)
Article
Oncology
Rachel W. Chan, Liam S. P. Lawrence, Ryan T. Oglesby, Hanbo Chen, James Stewart, Aimee Theriault, Mikki Campbell, Mark Ruschin, Sten Myrehaug, Eshetu G. Atenafu, Brian Keller, Brige Chugh, Scott MacKenzie, Chia-Lin Tseng, Jay Detsky, Pejman J. Maralani, Greg J. Czarnota, Greg J. Stanisz, Arjun Sahgal, Angus Z. Lau
Summary: This study described the implementation and initial results of using CEST for monitoring patients with CNS tumours treated with a 1.5 tesla MR-guided radiotherapy system. The results showed that CEST MRI is feasible for in vivo imaging of CNS tumours, displaying tumor/white-matter contrast, temporal signal changes, and associations with tumor grade.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Brady S. Laughlin, Alvin C. Silva, Sujay A. Vora, Sameer R. Keole, William W. Wong, Michael H. Schild, Steven E. Schild
Summary: This retrospective study demonstrated the long-term efficacy of treating prostate cancer using intensity modulated radiation therapy (IMRT) with the incorporation of MRI-guided boost. The results showed that MRI-guided localized dose intensification can provide high long-term disease control while maintaining favorable long-term toxicity.
FRONTIERS IN ONCOLOGY
(2022)